Evaluation of Shift, a smartphone application for Junior Medical Officers in New South Wales during the COVID-19 epidemic.

Phase 1

Active, not recruiting

• Conditions: Depression; Anxiety; COVID-19-related anxiety; Mental Health - Depression; Mental Health - Anxiety; Public Health - Health promotion/education

• Registration Number: ACTRN12620000571976
• Lead Sponsor: SW Sydney (University of New South Wales, Sydney)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-15
• Last Update Posted: 21 September 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 221

Inclusion Criteria

The inclusion criteria requires participants to be:
-Willing to provide consent to participate, and
-Currently employed as a Junior Medical Officer (Intern, Resident, Registrar or Junior Career Medical Officer) in New South Wales, and
-Own an internet-enabled smartphone with an Apple or Android operating system

Exclusion Criteria

Candidates will be excluded from the study if they:
-Do not provide consent to participate, or
-Are not currently employed as a Junior Medical Officer in New South Wales, or
-Do not own an internet-enabled smartphone with an Apple or Android operating system

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression symptom change:<br>Depression will be measured using the Patient Health Questionnaire (PHQ-9), a reliable and valid nine-item screening tool to assess depression severity over the past fortnight. The PHQ-9 also includes a single item assessing level of difficulty in daily functioning due to depressive symptoms.[Depression symptoms will be assessed at baseline and post intervention (occurring between 4 and 6 weeks post baseline) ];Anxiety Symptom change: <br>The Generalised Anxiety Disorder scale (GAD-7) is a reliable and valid seven-item screener for generalised anxiety symptoms. The GAD-7 also includes a single item assessing level of difficulty in daily functioning due to anxiety-related symptoms.[Anxiety symptoms will be assessed at baseline and post intervention (occurring between 4 and 6 weeks post baseline) ]